ScreenerHero

PASGPassage Bio, Inc.

NAS · US · Healthcare · Biotechnology · passagebio.com
4.440USD-1.55%Mkt Cap: 14.29M $P/E: —

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap14.29M $
Enterprise Value-9.74M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.52M $
Revenue/Share—
Last Price4.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.43
PEG—
EV/EBITDA0.26
EV/Revenue—
P/S—
P/B3.23
EPS (TTM)-11.32
EPS (Forward)-10.39
52W Range
3.2957% of range20.00
52W High20.00 USD
52W Low3.295 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-242.72%
ROA-73.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.51M $
CapEx (TTM)—
FCF Margin—
FCF Yield-103.69%
Net Debt-24.16M $
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity1.28
Current Ratio1.22
Quick Ratio1.17
Book Value/Sh1.385 USD
Cash/Share7.507 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 14, 2025
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+249.1%
Target Range8.000 USD – 23.00 USD
$8.000+249.1% to mean$23.00
# Analysts2
Ownership
Shares Out.3.22M
Float3.20M
Insiders7.71%
Institutions136.10%
Short Interest
Short Ratio3.6d
Short % Float6.04%
Short % Out.4.84%
Shares Short155.84K
Short (prev mo.)114.19K
Technical
SMA 504.837 (-8.2%)
SMA 2007.770 (-42.9%)
Beta1.43
S&P 52W Chg18.16%
Avg Vol (30d)28.89K
Avg Vol (10d)10.64K
Technical Indicators
RSI (14)41.9
MACD-0.1028
MACD Signal-0.1243
MACD Hist.+0.0216
BB Upper4.853 USD
BB Middle4.555 USD
BB Lower4.257 USD
BB Width13.08%
ATR (14)0.3115 USD
Vol Ratio (20d)2.15x